Paper8622019
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J and 13 others. J Clin Oncol, 1996. Cited by 1,163 papers, by iCite.
Cite this record
ConductScience Library. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Papers, record 8622019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8622019
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
- PubMed
- Publication types
- Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Breast Neoplasms | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Adult | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Infusions, Intravenous | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Proto-Oncogene Mas |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P50-CA58207 | NCI NIH HHS | United States | P50CA058207 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02758080 | Matching Patients With Hematologic Malignancy to Adequate Clinical Trials | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 8622013 | Should we treat HER, too? | https://conductscience.org/library/papers/8622013 |
Source PubMed
Cited by286
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,163 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41414806 | Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates. | Cancer Res Treat | 2026 | https://conductscience.org/library/papers/41414806 | PubMed |
| 40437017 | Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40437017 | PubMed |
| 39681638 | PDX models for functional precision oncology and discovery science. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/39681638 | PubMed |
| 39271787 | Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/39271787 | PubMed |
| 39177768 | Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients. | Cancer Chemother Pharmacol | 2024 | https://conductscience.org/library/papers/39177768 | PubMed |
| 39138287 | CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing. | Commun Biol | 2024 | https://conductscience.org/library/papers/39138287 | PubMed |
| 38911570 | Twenty-five years with HER2 targeted therapy. | Ann Transl Med | 2024 | https://conductscience.org/library/papers/38911570 | PubMed |
| 38827026 | Oncogenes and tumor suppressor genes: functions and roles in cancers. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/38827026 | PubMed |
| 38355821 | Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA). | Breast Cancer Res Treat | 2024 | https://conductscience.org/library/papers/38355821 | PubMed |
| 38191924 | Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/38191924 | PubMed |
| 38175349 | Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer. | Cancer Treat Res | 2023 | https://conductscience.org/library/papers/38175349 | PubMed |
| 37895921 | The History and Development of HER2 Inhibitors. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37895921 | PubMed |
| 37463446 | Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer. | J Clin Invest | 2023 | https://conductscience.org/library/papers/37463446 | PubMed |
| 37280713 | Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. | Breast Cancer Res | 2023 | https://conductscience.org/library/papers/37280713 | PubMed |
| 37240498 | History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer. | J Clin Med | 2023 | https://conductscience.org/library/papers/37240498 | PubMed |
| 37174034 | Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37174034 | PubMed |
| 36761943 | Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky. | Front Oncol | 2023 | https://conductscience.org/library/papers/36761943 | PubMed |
| 36636439 | Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review. | JACC CardioOncol | 2022 | https://conductscience.org/library/papers/36636439 | PubMed |
| 36454979 | The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis. | PLoS One | 2022 | https://conductscience.org/library/papers/36454979 | PubMed |
| 35757801 | Biomaterials-Mediated Tumor Infarction Therapy. | Front Bioeng Biotechnol | 2022 | https://conductscience.org/library/papers/35757801 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8622019
GET https://conductscience.org/api/papers/v1/8622019/cited_by?page=2